J&J unveils PhIIa data of oral antiviral for dengue fever prevention
20 Oct 2023
Phase 2Clinical Result
Johnson & Johnson’s oral antiviral has shown hints of activity in a Phase IIa human challenge trial for the prevention of mosquito-borne disease dengue fever, a category historically riddled with challenges.
The trial is studying three dosing regimens of JNJ-1802 versus placebo in 54 healthy adults at sites in more than 10 countries. The subjects received treatment or placebo daily and were exposed to attenuated dengue 3 serotype (DENV-3) five days in. They continued to get daily treatment or placebo for 26 days.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.